Every Form 4 that RenovoRx, Inc. (RNXT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RNXT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNXT filings page.
RenovoRx, Inc. (symbol: RNXT) is the issuer of record for a Form 4 filing submitted to the SEC. VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. (RNXT) reported that its Chief Financial Officer, Mark Voll, received a grant of 80,000 restricted stock units (RSUs)222,380 shares of common stock directly and 97,200 shares indirectly through the Voll Family Trust. No Rule 10b5-1 trading plan is reported for this award.
RenovoRx, Inc. director Una S. Ryan, through The Una S. Ryan Revocable Trust, reported several "other" transactions in RenovoRx common stock classified as restructuring events rather than open-market trades. The filing shows a total of 97,165 shares involved in these non-derivative restructurings, all held indirectly by the trust after the reported changes.
Footnotes explain that the activity reflects distributions of RenovoRx shares from Astria Fund and Golden Seeds Venture Fund GP, entities where Ryan is a non-managing member. These entries reorganize how her indirect holdings are structured, with no reported open-market buying or selling.
RenovoRx, Inc. Chief Financial Officer Mark Voll reported an open-market purchase of 25,000 shares of Common Stock at $0.7876 per share on May 19, 2026. Following this purchase, he directly holds 142,380 shares and indirectly holds 97,200 shares through the Voll Family Trust.
A prior grant of 58,953 restricted stock units (RSUs) for his future CFO service remains partly unvested. As of April 30, 2026, 8,823 RSUs had vested and 50,130 RSUs were still unvested.
RenovoRx, Inc. Chief Executive Officer Shaun Bagai received a grant of stock options covering 946,107 shares of common stock at an exercise price of $0.98 per share. The grant was approved by the Compensation Committee.
The options vest over four years at 1/48 per month starting January 1, 2026, becoming fully vested on January 1, 2030, and expiring on April 3, 2036. They are only exercisable when there is an effective registration statement covering the underlying shares.
VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. reported that Chief Financial Officer Mark Voll received an award of 80,000 shares of Common Stock on April 3, 2026, reflecting stock-based compensation rather than an open-market purchase. The award stems from grants of restricted stock units for his service as CFO.
The footnote explains this consists of 8,777 RSUs for February 2026, 12,270 RSUs for March 2026, and 58,953 RSUs for future service, with the February and March RSUs fully vested upon grant and the remainder vesting monthly. After the transaction, he holds 117,380 shares directly and 97,200 shares indirectly through the Voll Family Trust.
RenovoRx, Inc. reported that Chief Clinical Officer Leesa Gentry received a grant of stock options to purchase up to 128,550 shares of common stock at an exercise price of $0.98 per share. The options vest over four years at a rate of 1/48 per month, with vesting starting on January 1, 2026, and becoming fully vested on January 1, 2030.
The options are exercisable only when there is an effective registration statement covering the underlying shares and will expire on April 3, 2036. Following this grant, Gentry holds 128,550 stock options directly.
RenovoRx, Inc. granted its Chief Medical Officer, Ramtin Agah, stock options to purchase 621,727 shares of common stock. The options have an exercise price of $0.98 per share and were approved by the Compensation Committee.
The grant consists of 319,073 shares underlying incentive stock options and 302,654 shares underlying non-qualified stock options. Vesting occurs over four years at 1/48 per month, beginning January 1, 2026, becoming fully vested on January 1, 2030. The options are exercisable only when there is an effective registration statement covering the underlying shares and will expire on April 3, 2036. Following this award, the reporting person holds 621,727 derivative securities.
VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. chief financial officer Mark Voll reported an equity grant of 12,380 shares of common stock. These shares were granted as restricted stock units for his service as a consultant of the company for January 2026 and carry a stated price of $0.00 per share.
Following this grant, Voll directly holds 37,380 shares of common stock and has an additional 97,200 shares reported as indirectly held through the Voll Family Trust DTD 6/23/2010, with Mark Voll as trustee. This filing reflects compensation rather than an open-market stock purchase.
RenovoRx director Marton Laurence, through his Laurence Marton Rollover IRA, bought securities in a private placement. The IRA acquired 4,860 warrants and 9,720 shares of RenovoRx common stock for an aggregate purchase price of $10,000.
The warrants are immediately exercisable at $1.9326 per share and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.
RenovoRx, Inc. director and CEO Shaun Bagai reported indirect purchases through The Bagai Family Trust on March 20, 2026. The trust bought 24,300 shares of common stock and 12,150 warrants in a private placement for an aggregate of $25,000.
After these transactions, the trust holds 313,357 shares of common stock and 12,150 warrants, while Bagai also holds 50,983 shares directly. The warrants are exercisable immediately and can be converted into 12,150 shares of common stock at an exercise price of $1.9326 per share.
The warrants expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.
RenovoRx, Inc. Chief Financial Officer Mark Voll, through the Voll Family Trust, reported buying both common stock and warrants in a private placement. The trust acquired 97,200 shares of common stock and 48,600 warrants, for an aggregate purchase price of $100,000.
The warrants are exercisable immediately at $1.9326 per share of underlying common stock and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter.
RenovoRx, Inc. Chief Medical Officer and director Ramtin Agah reported an open market purchase of the company’s common stock. On January 21, 2026, he bought 10,000 shares of RenovoRx common stock in open market transactions at a weighted average price of $0.9975 per share. The filing notes that the shares were acquired in multiple trades at prices ranging from $0.995 to $1.00 per share. Following this purchase, Agah directly holds 798,460 shares of RenovoRx common stock.
RenovoRx, Inc. director and Chief Medical Officer Ramtin Agah reported buying 12,000 shares of the company’s common stock in an open market transaction on December 16, 2025, at a price of $0.85 per share.
After this purchase, he beneficially owns 778,460 shares of RenovoRx common stock, held directly. Agah serves as both a director and an officer, so this transaction increases his personal equity stake alongside his leadership responsibilities at the company.
RenovoRx, Inc. insider trading report: Director and Chief Medical Officer Ramtin Agah reported open market purchases of RenovoRx common stock. On 11/21/2025, he bought 10,000 shares at a price of $0.80 per share, and on 11/24/2025 he purchased an additional 12,000 shares at $0.80 per share. After these transactions, he beneficially owned 756,460 shares of RenovoRx common stock, held directly. The filing notes that these transactions reflect open market purchases of the company’s securities.
RenovoRx, Inc. director Laurence J. Marton reported a non‑derivative transaction and a derivative grant on 10/01/2025. He was granted 47,640 stock option awards with an exercise price of $1.34, exercisable beginning 10/01/2025 and expiring 10/01/2035. The option shares vest in 12 equal monthly installments starting 11/01/2025. The Form 4 was signed and filed on 10/03/2025. The report lists Mr. Marton as a director and the filing indicates the options are held directly.
RenovoRx director Una S. Ryan was granted a stock option on 10/01/2025 to purchase 47,640 shares of common stock at an exercise price of $1.34 per share. The option vests in 12 equal monthly installments beginning 11/01/2025 and expires on 10/01/2035. Following the grant, Ms. Ryan directly beneficially owns 47,640 options. The Form 4 was signed on 10/02/2025 and shows the filing was made by a single reporting person.